Beta Amyloid Peptide: Research Paper : Evidences for Agmatine alterations in Aβ 1-42 induced Memory Impairment in Mice

Evidences for Agmatine alterations in Aβ 1-42 induced Memory Impairment in Mice

Abstract

Alzheimer's disease is an age related progressive neurodegenerative disorder characterized by decline in cognitive functions, such as memory loss and behavioural abnormalities. The present study sought to assess alterations in agmatine metabolism in the beta-amyloid (Aβ1-42) Alzheimer's disease mouse model. Aβ1-42 injected mice showed impairment of cognitive functioning as evidenced by increased working and reference memory errors in radial arm maze (RAM). This cognitive impairment was associated with a reduction in theagmatine levels and elevation in its degrading enzyme, agmatinase, whereas reduced immunocontent was observed in its synthesizing enzyme arginine decarboxylase expression within hippocampus and prefrontal cortex. Chronic agmatine treatment and its endogenous modulation by L-arginine, or arcaine or aminoguanidine prevented the learning and memory impairment induced by single intracranial Aβ1-42 peptide injection. In conclusion, the present study suggests the importance of the endogenous agmatinergic system in β-amyloid induced memory impairment in mice.

Keywords: Agmatine; Alzheimer's disease; Cognitive impairment; β-Amyloid.

Copyright © 2020. Published by Elsevier B.V.

This article originally appeared in the "https://pubmed.ncbi.nlm.nih.gov/33127446/" and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice.